USA-based Tranzyme Pharma (Nasdaq: TZYN) and independent Dutch drugmaker Norgine have announced disappointing top-line results of the primary analysis of ULISES 008, the second of two Phase III pivotal trials evaluating ulimorelin in postoperative ileus.
Consistent with the ULISES 007 data released earlier this year (The Pharma Letter March 12), ULISES 008 did not meet the primary and secondary endpoints as there was no statistical difference between the ulimorelin and placebo groups. The two trials were identical in design and population.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze